A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Superficial Bladder Cancer

Trial Profile

A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Superficial Bladder Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs SCH 721015 (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors FKD Therapies
  • Most Recent Events

    • 24 Aug 2017 Results published in The Society of Urologic Oncology and the Society of Urologic Oncology Clinical Trials Consortium media release.
    • 23 Aug 2017 Results published in the Journal of Clinical Oncology
    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top